ACCC to Develop Comprehensive Program on Immuno-Oncology for Community‐Based Providers

Get Permission

ACCC is pleased to have the opportunity to help ensure [that] cutting-edge therapies can be delivered in the community setting.

—Becky L. DeKay, MBA

The Association of Community Cancer Centers (ACCC) has been provided with a contribution to develop a comprehensive program in immuno-oncology for community-based providers. The funding, provided by Bristol-Myers Squibb, will enable ACCC to establish the Institute for Clinical ImmunoOncology to educate providers about immuno-oncology and its implementation and delivery in the community setting.

The Institute for Clinical Immuno-Oncology will be a catalyst in assuring the availability of and access to innovative immune-oncology agents and therapies for patients in need.

Immuno-oncology, a transformational paradigm in cancer treatment, focuses on developing therapies that put the body’s own immune system to work to fight cancer.

“We are thrilled about the opportunity to help our members adopt innovations,” said Becky L. DeKay, MBA, President of ACCC. “There have been exciting advancements in understanding the immune system over the last 5 years, and this has led to newly emerging immunotherapy treatments. ACCC is pleased to have the opportunity to help ensure these cutting-edge therapies can be delivered in the community setting.”

Advisory Committee to Be Assembled

The Institute for Clinical Immuno-Oncology will engage community thought leaders and providers to advance the science and clinical applications of immune-oncology therapeutics in the community setting through the collective expertise, experience, and insights of leading providers.

The initial phase of the program will involve the establishment of the project infrastructure, including staffing, project planning, and marketing, and identification of potential partner organizations. An Advisory Committee consisting of ACCC members and other immune-oncology leaders will be created to oversee the planning and development of the Institute.

Early phases of the program will include the identification and engagement of clinician scholars and thought leaders, an educational needs assessment of the ACCC membership, a 1day national conference, a monthly series of ecourses and enewsletters for clinicians and fellows, and multiple scientific and policy publications highlighting the project findings and ­outcomes. ■